DDB1
DNA damage-binding protein 1
As of the edition of 20 October 2026, DDB1 (DNA damage-binding protein 1, UniProt Q16531) has 1 drug tested at it and 1 company on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q16531
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- Inside the cell
- Solved structures
- 226
- Disease areas
- Immune system; Cancer; Blood and lymph; Heart and blood vessels; Skin and connective tissue; Inherited and neonatal; Nutrition and metabolism; Pregnancy and women's health
- Registered trials of its drugs
- 54
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Total | 1 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Iberdomide | Marketed | Phase 3 | Ends 2031 |
1 of 1 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Undetermined | 1 |
| Total on the list | 1 |